Core Viewpoint - The "Healthy China 2030" plan emphasizes achieving national health and longevity as a key indicator of national prosperity and revitalization, with a focus on high-quality development in the domestic pharmaceutical industry [1] Group 1: Company Overview - Qilu Pharmaceutical, representing the industry, adheres to the philosophy of "integrating creation and imitation," with a planned R&D investment exceeding 4.3 billion yuan in 2024 and a cumulative investment of over 20 billion yuan during the 14th Five-Year Plan period [3] - The company has established R&D centers in multiple locations, including Seattle, San Francisco, Boston, Shanghai, Hainan, and Jinan, employing over 5,200 dedicated R&D personnel [3] Group 2: Product and Market Impact - Qilu Pharmaceutical's product Medaxin® was included in the national drug centralized procurement list in December 2019, benefiting over 100 million cardiovascular disease patients in China and significantly reducing their economic burden [1] - As of November this year, Qilu has 109 products that have won bids or renewed contracts, with 30 centralized procurement drugs exported to 33 countries and regions [1] Group 3: Research and Development Achievements - The company is currently developing over 80 innovative drugs and is efficiently advancing 20 of them through clinical trials [3] - Qilu Pharmaceutical leads the industry in several metrics, including nearly 300 brand-name generic drugs in development, and has the highest number of consistency evaluations and national centralized procurement wins [5] - The company has launched 16 biosimilars and holds 530 invention patents, with 42 major new drug creation projects under the national science and technology major special program since the 12th Five-Year Plan [5] Group 4: Global Strategy - Qilu Pharmaceutical implements a "global consistency, co-line production" strategy and has been conducting simultaneous submissions for drug approvals in China and international regulatory bodies since 2013 [5] - It is the only domestic pharmaceutical company exporting formulations to the EU, the US, the UK, Japan, Australia, and Canada, with 38 products holding the top market share in their respective overseas markets, serving approximately 1.5 billion people globally each year [5]

Group 1 - The core viewpoint of the article emphasizes the transition of China's pharmaceutical industry from a major player to a strong player through technological innovation, particularly in the context of the "Healthy China" strategy [1] - The "High-Quality Development of Domestic Medicines Research and Symposium" held in Jinan highlighted key discussions on innovative drug research and development, quality improvement of generic drugs, and the construction of an industrial ecosystem [3] - The dual drive of policy and industry is pushing domestic pharmaceuticals into a phase of high-quality development, with a significant increase in the number of clinical trials for innovative drugs, which have grown at an annual rate of over 20% [4] Group 2 - Qilu Pharmaceutical, a leading domestic pharmaceutical company, has adopted a "dual focus on innovation and generics" strategy, maintaining over 10% of its revenue for R&D investment, with an expected R&D expenditure exceeding 4 billion yuan by 2025 [4][6] - In the innovative drug sector, Qilu Pharmaceutical has developed a comprehensive innovation platform that spans drug discovery to commercialization, with recent clinical data from two innovative anti-tumor drugs attracting industry attention [5] - Qilu Pharmaceutical has over 20 innovative drugs in various clinical stages and has achieved significant breakthroughs in generic drugs, with 219 products passing consistency evaluations, leading to a reduction in patient costs by over 60% for certain medications [6] Group 3 - The company is accelerating its global layout, establishing three R&D centers in the U.S. and exporting products to over 100 countries, with more than 50 products in major regulatory markets [7] - Qilu Pharmaceutical is extending its supply chain by integrating upstream raw material production and downstream drug distribution, creating a comprehensive industrial ecosystem [7] - Industry experts note that Qilu Pharmaceutical's development path reflects the core logic of high-quality development in domestic pharmaceuticals, with a focus on generics ensuring access to essential medicines and innovative drugs driving technological breakthroughs [8]

Core Insights - The article highlights the transformation of China's pharmaceutical industry from a "big pharmaceutical country" to a "strong pharmaceutical country," emphasizing the importance of high-quality development and innovation in the sector [2][3] Group 1: Event Overview - The "High-Quality Development Research Tour of Domestic Medicines" was successfully held in Jinan, Shandong, from June 4 to June 6, 2025, organized by the China Pharmaceutical News Information Association and Beijing Daily Client [1] - The event involved over 20 major media outlets, focusing on the research and innovation platform, quality management system, and intelligent production base of Qilu Pharmaceutical [1] Group 2: Qilu Pharmaceutical's Achievements - Qilu Pharmaceutical has won 7 National Science and Technology Progress Awards and has 208 products listed in the National Medical Insurance Directory as of June 2025 [2] - The company has achieved leadership in the industry in terms of consistency evaluation, first-time evaluations, and national procurement bidding [2] - Qilu's R&D investment has increased from 5%-8% of sales revenue to 10%-12%, with an expected cumulative investment exceeding 20 billion yuan during the 14th Five-Year Plan period [3] Group 3: International Expansion - Qilu Pharmaceutical is the only domestic company exporting formulations to major regulatory markets including Europe, the US, Japan, Australia, and Canada, with 38 products holding the top market share in their respective regions [4] - The company's export revenue reached 1.02 billion USD in 2024 [4] Group 4: Technological Innovations - Qilu has developed groundbreaking technologies such as dual-function combination antibody preparation technology and large-scale cell culture technology, establishing an internationally leading MabPair combination antibody technology platform [6] - The company has implemented fully automated production lines, ensuring quality consistency and traceability throughout the production process [5] Group 5: Industry Dialogue - A seminar titled "Quality Leads, Good Medicines Accessible" was held during the research tour, where experts discussed the need for improved public perception of domestic medicines and the importance of collaborative efforts among media, academia, and regulatory bodies [6] - Qilu has 15 products among those selected in national procurement that rank highly in the US market [6] Group 6: Future Directions - The "High-Quality Development Research Tour of Domestic Medicines" will continue to focus on the pharmaceutical industry, expanding research to more domestic pharmaceutical companies across the country [7]

Core Insights - The event "High-Quality Development of Domestic Pharmaceuticals" was held at Qilu Pharmaceutical Group, aimed at showcasing the true quality of domestic drugs and the achievements of China's manufacturing industry [1][3] - A seminar was conducted where industry experts and media representatives discussed the challenges and opportunities in the high-quality development of domestic pharmaceuticals [3][5] Group 1: Industry Overview - The event was organized by the China Pharmaceutical News Information Association, focusing on quality management systems, R&D innovation platforms, and intelligent manufacturing bases [1] - Experts emphasized the need for strong promotion and scientific communication to enhance the brand image of domestic pharmaceuticals, highlighting their quality, international standing, and contributions to public health [3] Group 2: Company Insights - Qilu Pharmaceutical, as a leading domestic pharmaceutical company, shared its experiences in innovation, smart manufacturing, and international quality system construction [3][5] - The company has over 300 products on the market, with more than 70 being the first or exclusive in China, significantly reducing the economic burden on the national healthcare system [7][9] Group 3: R&D and Innovation - Qilu Pharmaceutical is actively developing over 80 innovative drug projects, with two national class I new drugs already launched [9] - The company has established six R&D centers in the U.S. and is focused on high-end new formulations, achieving breakthroughs in various advanced drug delivery systems [9] Group 4: Market Position and Strategy - Qilu Pharmaceutical has a leading market share in domestic clinical prescriptions and is expanding its presence in international markets, with nearly 40 formulation products in regions like the U.S., EU, Japan, and Australia [7][9] - The company has won bids for 100 drugs under the national drug procurement policy, significantly lowering drug prices to benefit the public [9]